HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss

Transplantation

Volumn 88, Issue 4, 2009, Pages 568-574

  Lee, Po Chang ^a   Zhu, Lan ^b   Terasaki, Paul I ^b   Everly, Matthew J ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Alloantibodies; Allograft survival; Chronic rejection; HLA; Transplantation

Indexed keywords

HLA ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL;

ADULT; ANTIBODY SPECIFICITY; CASE-CONTROL STUDIES; CHRONIC DISEASE; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 70349112303     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b11b72     Document Type: Article

References (34)

1. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
2. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
3. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
4. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
5. Mizutani K, Shibata L, Ozawa M, et al. Detection of HLA and MICA antibodies before kidney graft failure. Clin Transpl 2006: 255.
6. Ozawa M, Rebellato LM, Terasaki PI, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006: 265.
7. Kinukawa T, Kato M, Terasaki PI, et al. Retrospective antibody analysis of thirty patients with kidney graft failure. Clin Transpl 2006: 291.
8. van den Berg-Loonen EM, Terasaki P, Kohanof S, et al. Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience. Clin Transpl 2006: 305.
9. Terasaki P, Lachmann N, Cai J. Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transpl 2006: 455.
10. Ozawa M, Terasaki PI, Lee JH, et al. 14th International HLA and immunogenetics workshop: Report on the prospective chronic rejection project. Tissue Antigens 2007; (69 suppl 1): 174.
11. Terasaki PI, McClelland JD. Microdroplet assay of human serum cyto-toxins. Nature 1964; 204: 998.
12. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
13. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3: 1488.
14. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408.
15. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662.
16. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothe-lial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357: 33.
17. Tang AH, Platt JL. Accommodation of grafts: Implications for health and disease. Hum Immunol 2007; 68: 645.
18. Takahashi K, Saito K. Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006; 13: 118.
19. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652.
20. Langan LL, D'Orsogna L, Park LP, et al. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: Updated results of a single-center cross-sectional study. Clin Transpl 2006; 219.
21. Lachmann N, Terasaki PI, Schonemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up. Clin Transpl 2006: 171.
22. Gerbase-DeLima M, Campos EF, Tedesco-Silva H, et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006: 201.
23. Pelletier RP, Hennessy PK, Adams PW, et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134.
24. Worthington JE, Martin S, Barker AJ, et al. The role of HLA-specific antibodies in kidney transplant rejection: Published studies and local data. Clin Transpl 2006: 349.
25. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
26. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
27. Langan LL, Park LP, Hughes TL, et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007; 7: 847.
28. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothe-lium. Kidney Int 2001; 59: 488.
29. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
30. Muczynski KA, Ekle DM, Coder DM, et al. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336.
31. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, et al."Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111.
32. Everly M, Everly J, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection Transplantation 2008; 86: 1754.
33. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2008; 9: 201.
34. Trived HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.